RATIONALE: A 2016 AAAAI position statement recommended routine evaluation of beta-lactam allergies due to the burden of pervasive mislabeled allergies. This quality improvement study implemented strategies to expedite evaluation at Rady Children's Hospital. METHODS: A real-time list of inpatients with beta-lactam allergies, Best Practice Advisory and automatic referral was created in EPIC. Pharmacy staff documented reactions using a standardized Smartform aimed at distinguishing reaction types (i.e., immediate vs delayed). The Smartform was also used to document reactions of outpatients in Allergy Clinic. Skin testing was performed for first-day reactions, a raised and mobile rash, or by family request. Children with negative skin testing or with non-severe delayed reactions were given graded challenges. RESULTS: 118 patients (15 months to 24 years) were interviewed over 4 months. 34 were evaluated in clinic. 11 (32%) had skin testing. 2 skin tests were positive, and 3 skin tests were incomplete due to discomfort; however, the part performed was negative and the patients passed challenges. The time interval between reaction and testing ranged from 1 month to 14 years. There were no adverse reactions, including during the week following challenge. 32 (94%) of patients evaluated in clinic, and 100% of those offered the challenge, passed. Of 84 admitted patients, 36 (43%) had history that qualified them for skin testing (43%). CONCLUSIONS: This project adapted EPIC tools to expedite evaluation of beta-lactam allergies. Our results suggest that skin testing may not be necessary for the majority of children labeled with a beta-lactam allergy.
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Angiopoietin-2 Is Released Only at Late Phase of Systemic Anaphylaxis in Awake Rats
Prof. Toshishige Shibamoto, Dr. Tao Zhang, Dr. Mamoru Tanida, Dr. Yuhichi Kuda, Prof. Yasutaka Kurata; Kanazawa Medical University, Uchinada, Japan. RATIONALE: Angiopoietin (Angpt)-2, a endothelium derived permeability-increasing endothelial growth factor, is released in response to anaphylactic mediators such as histamine and leukotrienes, and is involved in vascular leakage of sepsis and acute lung injury. We hypothesized that Angpt-2 is released and may augment hyperpermeability during anaphylactic hypotension. Thus, we determined the plasma Angpt-2 levels during anaphylactic hypotension in awake ovalbumin-sensitized Sprague Dawley rats. METHODS: The sensitized (n 5 6), and non-sensitized (n 5 6) rats were intravenously injected with the antigen (0.6 mg) under un-anesthetized state. Mean blood pressure (MBP) was measured, and hematocrit (Hct) and plasma Angpt-2 levels were assessed at baseline and at 6, 20 and 60 min, and 2, 6 and 24 h after antigen. RESULTS: In sensitized rats, at 6 min after antigen, MBP decreased to the nadir of 58610 (SD) mmHg from the baseline (10663 mmHg). Hct increased to the peak of 5563% from the baseline (4261%) at 20 min after antigen, followed by a gradual decline. Consequently, MBP and Hct recovered to the baseline at 1 and 2 h, respectively. These results suggest that anaphylaxis-induced plasma extravasation peaked within 1 h. Plasma Angpt-2 levels did not increase significantly from the baseline of 2062 ng/ml until 1 h after antigen (2763 ng/ml), thereafter increased gradually reaching the peak of 5466 ng/ml (2.7 fold baseline) at 6 h, followed by a return to the baseline at 24 h. CONCLUSIONS: Angpt-2 is released only at late phase and is not involved in early vascular leak during anaphylactic hypotension in awake rats. 
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